ReviewInternational journal of molecular sciences2021
Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 42 citations in OpenAlex.
- An engineered bacteria-chitosan hybrid robot for lactate depletion and synergistic STING activation to potentiate bladder cancer immunotherapy.Materials today. Bio · 2026Article
- Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer.Oncology and therapy · 2026Review
- A multi-modal approach for decision making in bladder cancer.Nature reviews. Urology · 2026Review
- Intratumoral and Peritumoral Fat CT‑Based Radiomics for Predicting Recurrence Risk in Non-Muscle-Invasive Bladder Cancer: A Two-Center Study.Annals of surgical oncology · 2026Article
- A radiomics-driven machine learning model for predicting bladder cancer prognosis identifies genes associated with radiomic features.Clinical & experimental metastasis · 2025Article
- Genetic Variants of AGO1*rs595961 and AGO2*rs4961280 with Susceptibility to Bladder Carcinoma.Indian journal of clinical biochemistry : IJCB · 2025Article
- Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer.Cancer medicine · 2025Review
- Efficacy and safety of BCG and immune checkpoint inhibitors in non-muscle invasive bladder cancer: A meta-analysis with exploratory chemotherapy comparisons.Oncology letters · 2025Article
- BAP1-mediated ubiquitination inhibition and CAS6/AXL signaling activation in bladder cancer progression.Cytotechnology · 2025Article
- A small molecule directly targets NLRP3 to promote inflammasome activation and antitumor immunity.Cell death & disease · 2025Article
- Molecular biomarkers of progression in non-muscle-invasive bladder cancer - beyond conventional risk stratification.Nature reviews. Urology · 2025Review
- Preclinical evaluation of bozepinib in bladder cancer cell lines: modulation of the NPP1 enzyme.Purinergic signalling · 2025Article
- PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG.World journal of urology · 2025Article
- Explainable machine learning model predicts response to adjuvant therapy after radical cystectomy in bladder cancer.Frontiers in oncology · 2025Article
- Advances in immunotherapy for bladder cancer and clinical practice of next-generation sequencing.Frontiers in immunology · 2025Review
- Lectin Receptors in Primary and Metastatic Cancer Cells.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Targeted Delivery of STING Agonist via Albumin Nanoreactor Boosts Immunotherapeutic Efficacy against Aggressive Cancers.Pharmaceutics · 2024Article
- Efficacy and safety of tislelizumab plus bacillus-calmette guérin with or without chemotherapy as a bladder-sparing treatment for high-risk non-muscle-invasive bladder urothelial cancer: a real-world study.Discover oncology · 2024Article
- Machine learning identifies the role of SMAD6 in the prognosis and drug susceptibility in bladder cancer.Journal of cancer research and clinical oncology · 2024Article
- Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In high-risk non-muscle invasive bladder cancer (HR-NMIBC), patient outcome is negatively affected by lack of response to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.